Anxiety Treatment: A Neurological Approach

Psychiatry focuses on symptom management through medication and psychotherapy. A neurological evaluation looks at the structural and metabolic machinery producing those symptoms. We measure cortisol rhythms, thyroid function, magnesium and B-vitamin levels, inflammatory markers, and autonomic nervous system balance. We use advanced neuroimaging to assess prefrontal cortex and amygdala function. The goal is not to replace psychiatric care but to identify the biological drivers that medications alone may not address. Many patients find that correcting an underlying metabolic deficit reduces anxiety severity in ways that adjusting psychiatric medication doses cannot.

Our evaluation includes a comprehensive metabolic panel measuring serum cortisol with diurnal rhythm assessment, thyroid hormones (TSH, free T3, free T4, thyroid antibodies), magnesium (RBC magnesium, not just serum), B-vitamin status (B6, B12, folate, methylmalonic acid), vitamin D, inflammatory markers (hs-CRP, homocysteine, ferritin), and markers of mitochondrial function and oxidative stress. These labs frequently reveal correctable deficiencies that are sustaining anxiety symptoms. Standard primary care panels do not include most of these tests.

Yes. Research by Shin and Liberzon (2010, Neuropsychopharmacology) and others has demonstrated that chronic anxiety is associated with measurable changes in brain structure and function. Amygdala hyperactivity, reduced prefrontal cortex gray matter volume, and altered connectivity between these regions have all been documented. Functional neuroimaging can reveal patterns of metabolic activity that distinguish anxiety-driven brain states from normal stress responses. These findings help us understand which circuits are dysregulated and guide treatment decisions.

No. We do not ask patients to discontinue psychiatric medications. Our treatments address the neurological and metabolic substrate that underlies anxiety, and they are designed to work alongside existing psychiatric care. Many patients find that as their metabolic deficiencies are corrected and neurological function improves, their psychiatrist is able to reduce medication doses over time. Any medication changes are made by the prescribing psychiatrist, not by us.

Chronic anxiety places enormous metabolic demands on the brain. Sustained amygdala activation and HPA axis overdrive consume cellular energy at rates that deplete NAD+ reserves. NAD+ is the central coenzyme in mitochondrial ATP production and a required cofactor for sirtuins involved in cellular stress response. When NAD+ is depleted, neurons cannot maintain normal energy output, oxidative damage accumulates, and neurotransmitter synthesis becomes impaired. Intravenous NAD+ replenishes these reserves directly, restoring the metabolic capacity that anxious brains need to regulate themselves.

The initial diagnostic evaluation, including lab work, neurological examination, and cognitive testing, is typically completed within the first one to two days. Lab results are reviewed with Dr. Orr, and a treatment protocol is built from those findings. The Intensive Brain Health Program is delivered over three to five consecutive days and includes IV-based therapies, metabolic optimization, and NeuroCoaching sessions. Most patients report measurable improvement in anxiety severity within two to four weeks of completing the program.

Several neurological conditions produce symptoms that are indistinguishable from primary anxiety disorders. Thyroid dysfunction, particularly hyperthyroidism, is the most common. Temporal lobe epilepsy can produce episodic fear and panic that is often misdiagnosed as panic disorder. Vestibular dysfunction causes a sense of unsteadiness that many patients interpret as anxiety. Pheochromocytoma, though rare, causes catecholamine surges that mimic panic attacks precisely. Vitamin B12 deficiency, iron deficiency, and mitochondrial dysfunction can all lower the threshold for anxiety symptoms. Our evaluation screens for each of these before attributing symptoms to a psychiatric cause alone.

Yes. We consider coordination with your existing mental health providers to be a necessary part of the process, not an optional courtesy. If our evaluation identifies a metabolic or neurological contributor to your anxiety, the treatment plan may include interventions that affect neurotransmitter levels or autonomic function. Your psychiatrist needs to know about those changes, particularly if you are on psychiatric medications whose dosing may need to be adjusted. With your permission, we send a detailed summary of findings and treatment recommendations to your providers.

Anxiety can cause all three of those symptoms through hyperventilation-induced alkalosis, sympathetic nervous system activation, and vestibular hypersensitivity. The clinical challenge is that peripheral neuropathy, vestibular disorders, and cervical spine pathology produce the same symptoms through entirely different mechanisms. We differentiate them with nerve conduction studies, vestibular testing, and targeted lab work. If the numbness follows a dermatomal or stocking-glove distribution, that points to a structural or metabolic cause. If dizziness is positional and reproducible, vestibular pathology is more likely. The evaluation answers the question rather than assuming the answer.